Cargando…

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Cerebrospinal fluid (CSF) tau (total tau, T‐tau), neurofilament light (NFL), and neurogranin (Ng) are potential biomarkers for neurodegeneration in Alzheimer's disease (AD). It is unknown whether these biomarkers provide similar or complementary information in AD. We examined 93 patients with A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mattsson, Niklas, Insel, Philip S, Palmqvist, Sebastian, Portelius, Erik, Zetterberg, Henrik, Weiner, Michael, Blennow, Kaj, Hansson, Oskar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048367/ https://www.ncbi.nlm.nih.gov/pubmed/27534871 http://dx.doi.org/10.15252/emmm.201606540

Ejemplares similares

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase
por: Becker, Bruno, et al.
Publicado: (2018)

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
por: Kvartsberg, Hlin, et al.
Publicado: (2015)

Molecular forms of neurogranin in cerebrospinal fluid
por: Nazir, Faisal Hayat, et al.
Publicado: (2020)

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2020)

Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke
por: De Vos, Ann, et al.
Publicado: (2017)

Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer’s Disease: A Pilot Study
por: Thordardottir, Steinunn, et al.
Publicado: (2020)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2018)

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

CSF neurogranin or tau distinguish typical and atypical Alzheimer disease
por: Wellington, Henrietta, et al.
Publicado: (2018)

Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease
por: Byrne, Lauren M., et al.
Publicado: (2018)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
por: Raket, Lars Lau, et al.
Publicado: (2020)

Plasma tau in Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Neurogranin and Neurofilament Light Chain as Preclinical Biomarkers in Scrapie
por: Betancor, Marina, et al.
Publicado: (2022)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders
por: Yilmaz, Aylin, et al.
Publicado: (2019)

Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays
por: Öhrfelt, Annika, et al.
Publicado: (2020)

Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology
por: Portelius, Erik, et al.
Publicado: (2018)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease
por: Cicognola, Claudia, et al.
Publicado: (2018)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2018)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease
por: Johansson, Per, et al.
Publicado: (2013)

Subtle Differences in Cognition in 70-Year-Olds with Elevated Cerebrospinal Fluid Neurofilament Light and Neurogranin: A H70 Cross-Sectional Study
por: Rådestig, Maya Arvidsson, et al.
Publicado: (2023)

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
por: Pereira, Joana B., et al.
Publicado: (2022)

Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease
por: Hellwig, Konstantin, et al.
Publicado: (2015)

The genetic regulation of protein expression in cerebrospinal fluid
por: Hansson, Oskar, et al.
Publicado: (2022)

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
por: Kvartsberg, Hlin, et al.
Publicado: (2018)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis
por: Mattsson, Niklas, et al.
Publicado: (2016)

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum
por: Gobom, Johan, et al.
Publicado: (2022)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1k9ah03i10bg0p7ojc9jig1t35